vTv Therapeutics (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday. They presently have a $2.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 3.00% from the company’s previous close.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Shares of NASDAQ VTVT traded down $0.04 during mid-day trading on Friday, reaching $2.67. The company had a trading volume of 1,180,413 shares, compared to its average volume of 5,511,327. vTv Therapeutics has a 52 week low of $0.65 and a 52 week high of $8.40. The stock has a market cap of $110.42 million, a PE ratio of -1.60 and a beta of -4.18.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. The company had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $2.06 million. Research analysts forecast that vTv Therapeutics will post -0.73 earnings per share for the current year.

In related news, major shareholder Ronald O. Perelman acquired 1,879,699 shares of the stock in a transaction dated Tuesday, November 6th. The stock was acquired at an average cost of $1.33 per share, with a total value of $2,499,999.67. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ronald O. Perelman purchased 815,217 shares of the stock in a transaction that occurred on Wednesday, January 16th. The stock was acquired at an average cost of $1.84 per share, with a total value of $1,499,999.28. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 5,389,833 shares of company stock worth $7,999,999. Insiders own 2.00% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Featured Article: Hedge Funds Explained

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.